J. W. Coons Advisors LLC Purchases 301 Shares of Stryker Co. (NYSE:SYK)

J. W. Coons Advisors LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 9.0% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,627 shares of the medical technology company’s stock after buying an additional 301 shares during the period. J. W. Coons Advisors LLC’s holdings in Stryker were worth $1,310,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of SYK. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Stryker by 78.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock valued at $45,260,000 after purchasing an additional 58,673 shares during the last quarter. OFI Invest Asset Management lifted its stake in shares of Stryker by 3,210.9% in the 2nd quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company’s stock valued at $1,062,000 after acquiring an additional 3,243 shares during the last quarter. Tidal Investments LLC boosted its holdings in shares of Stryker by 14.2% during the 1st quarter. Tidal Investments LLC now owns 13,558 shares of the medical technology company’s stock valued at $4,853,000 after acquiring an additional 1,681 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Stryker by 2.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock worth $210,289,000 after acquiring an additional 16,504 shares during the last quarter. Finally, Fiera Capital Corp grew its position in Stryker by 42.1% during the 2nd quarter. Fiera Capital Corp now owns 16,713 shares of the medical technology company’s stock worth $5,687,000 after acquiring an additional 4,948 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Viju Menon sold 600 shares of Stryker stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This trade represents a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. This represents a 17.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 67,381 shares of company stock worth $24,825,275. 5.50% of the stock is owned by corporate insiders.

Stryker Trading Up 1.8 %

Shares of SYK opened at $390.08 on Monday. The firm has a market cap of $148.71 billion, a P/E ratio of 41.81, a price-to-earnings-growth ratio of 2.94 and a beta of 0.91. Stryker Co. has a fifty-two week low of $282.35 and a fifty-two week high of $392.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The business has a 50-day moving average of $364.07 and a 200 day moving average of $347.54.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $2.46 earnings per share. As a group, research analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on SYK shares. Wells Fargo & Company lifted their price target on Stryker from $381.00 to $405.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Evercore ISI lifted their price target on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Royal Bank of Canada lifted their target price on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Canaccord Genuity Group upped their target price on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a report on Thursday. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $393.65.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.